Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
The Journal of Infection|April 30, 2026
Early antiretroviral therapy shapes the immunometabolic landscape without reducing the intact HIV reservoirPaula Suanzes, Judith Grau-Expósito, Jordi Navarro, et al.
The Lancet. HIV|February 28, 2024
Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trialGraeme Moyle, Lambert Assoumou, Nathalie de Castro, et al.
HIV Medicine|August 25, 2021
Chems4EU: chemsex use and its impacts across four European countries in HIV-positive men who have sex with men attending HIV servicesGary G Whitlock, Konstantinos Protopapas, Jose I Bernardino, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 11, 2024
Major cardiovascular events after COVID-19 in people with HIVRaquel Martín-Iguacel, Sergio Moreno-Fornés, Andreu Bruguera, et al.
Infectious Diseases Now|July 16, 2023
Clinical outcomes by supplemental oxygen use in remdesivir-treated, hospitalised adults with COVID-19Nadir Arber, Pallav L Shah, Lambert Assoumou, et al.
Cell Reports. Medicine|September 23, 2023
KLRG1 expression on natural killer cells is associated with HIV persistence, and its targeting promotes the reduction of the viral reservoirAntonio Astorga-Gamaza, David Perea, Nerea Sanchez-Gaona, et al.
Sexually Transmitted Infections|October 6, 2023
Impact of time of culture specimen collection on the recovery of Neisseria gonorrhoeae after a positive nucleic acid amplification testPatricia Nadal-Barón, Jesús Trejo-Zahinos, Jorge Nestor García, et al.
The New England Journal of Medicine|July 29, 2026
Phase 3 Trial of Weekly Oral Islatravir-Lenacapavir for HIV-1 TreatmentJürgen K Rockstroh, Moti N Ramgopal, Adrian Curran Fàbregas, et al.
JAMA Cardiology|December 11, 2024
Pitavastatin, Procollagen Pathways, and Plaque Stabilization in Patients With HIV: A Secondary Analysis of the REPRIEVE Randomized Clinical TrialMárton Kolossváry, Samuel R Schnittman, Markella V Zanni, et al.
AIDS (London, England)|November 11, 2025
Health-related quality of life among people with HIV at low-to-moderate risk for atherosclerotic cardiovascular disease in the REPRIEVE TrialMarissa R Diggs, Sarah M Chu, Kathleen V Fitch, et al.
Pageof 8